Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements.
Cedarbaum J, Silvestri M, Kutt H. Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements. Neurology 1990, 40: 995-7. PMID: 2345621, DOI: 10.1212/wnl.40.6.995.Peer-Reviewed Original ResearchConceptsInterrupted infusionTherapeutic response fluctuationsStriatal dopamine receptorsContinuous enteral infusionLevodopa dose requirementEnteral administrationEnteral infusionContinuous infusionDopamine receptorsInfusion rateParkinson's diseaseDose requirementsInfusionResponse fluctuationsMotor performanceLevodopaDiseasePatientsAdministrationReceptorsSustained‐release (+)‐PHNO [MK‐458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2‐receptor agonist administered as a long‐acting formulation
Cedarbaum J, Clark M, Toy L, Green‐Parsons A. Sustained‐release (+)‐PHNO [MK‐458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2‐receptor agonist administered as a long‐acting formulation. Movement Disorders 1990, 5: 298-303. PMID: 1979657, DOI: 10.1002/mds.870050407.Peer-Reviewed Original ResearchConceptsMK-458Disease patientsSelective D2 receptor agonistPostsynaptic dopamine receptorsMotor response fluctuationsD2 receptor agonistParkinson's disease patientsSustained-release formAdjunctive therapyD2 agonistDopamine receptorsSinemetParkinson's diseaseAgonistsResponse fluctuationsProgressive lossPatientsWeeksDiseaseDosageReduced sensitivityDaysTherapyReceptors